A. Swat

621 citations
6 papers · 374 · 1 hit paper · h-index 4

Impact in

  • Oncology top 10%
    • Cancer Immunotherapy and Biomarkers
    • Cancer Cells and Metastasis
    • HER2/EGFR in Cancer Research
    • CAR-T cell therapy research
    • Cancer Genomics and Diagnostics
    • Breast Cancer Treatment Studies

Papers in

    • Cancer Immunotherapy and Biomarkers 4
    • Cancer Treatment and Pharmacology 3
    • HER2/EGFR in Cancer Research 2
    • Advanced Breast Cancer Therapies 3
    • Prostate Cancer Treatment and Research 2

A. Swat

6 papers receiving 369 citations

A. Swat's Hit Papers

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis 2021 · 311 citations
3110+1+3Years since publication100200300

Peers

A. Swat
Comparison fields: 5 of 38
  • Oncology 254
  • Cancer Research 76
  • Immunology 73
  • Pulmonary and Respiratory Medicine 93
  • Radiology, Nuclear Medicine and Imaging 16
Replace P. Schmid with:
P. Schmid United States
Miao Ruan China
M.C. Liu United States
Aleksandra Łacko Poland
Shaochuan Liu China
Qing Jiang China
G. Scott Chandler United States
Maxime Borgeaud Switzerland
R. Dent Spain
Dagui Lin China
A. Swat relative to P. Schmid United States P. Schmid's profile →
Citations per field
00.5×1.5×2.5×
P. Schmid · 1×
Citations per year

Countries citing papers authored by A. Swat

Since Specialization
Citations

This map shows the geographic impact of A. Swat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Swat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Swat more than expected).

Fields of papers citing papers by A. Swat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Swat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Swat. The network helps show where A. Swat may publish in the future.

Co-authors

The 25 scholars most cited alongside A. Swat, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with A. Swat Line = papers co-authored together A. Swat links everyone, so they are left out of the graph.

All Works

6 of 6 papers shown
#Work
1
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
Hit paper breakdown →
2021311
2 202046
3 20208
4 20243
5 20173
6 20163

About A. Swat

A. Swat is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Infectious Diseases and Organic Chemistry, having authored 6 papers that have together received 374 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (4 papers), Cancer Treatment and Pharmacology (3 papers), Advanced Breast Cancer Therapies (3 papers), Breast Cancer Treatment Studies (2 papers), HER2/EGFR in Cancer Research (2 papers) and Prostate Cancer Treatment and Research (2 papers). The work is most often cited by research in Oncology (254 citations), Cancer Research (76 citations), Immunology (73 citations), Pulmonary and Respiratory Medicine (93 citations) and Radiology, Nuclear Medicine and Imaging (16 citations). A. Swat has collaborated with scholars based in Switzerland, Germany and United States. Frequent co-authors include Véronique Dièras, Andreas Schneeweiß, Carlos H. Barrios, Leisha A. Emens, Volkmar Henschel, Sherene Loi, Sylvia Adams, Hiroji Iwata, Shilpen Patel and Eric P. Winer. Their work appears in journals such as Annals of Oncology, Cancer Research and ESMO Open.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact